Drug name - Brukinsa

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(14 years from now)

CN104884458B BEIGENE Fused Heterocyclic Compounds As Protein Kinase Inhibitors
Apr, 2033

(10 years from now)

CN104884458A BEIGENE Fused Ring Compound As A Protein Kinase Inhibitor
Apr, 2033

(10 years from now)

IN201503521P2 BEIGENE Fused Heterocyclic Compounds As Protein Kinase Inhibitors
Apr, 2034

(11 years from now)

IN370291B BEIGENE Fused Heterocyclic Compounds As Protein Kinase Inhibitors
Apr, 2034

(11 years from now)

EP2989106B1 BEIGENE Fused Heterocyclic Compounds As Protein Kinase Inhibitors
Mar, 2042

(19 years from now)

EP2989106A1 BEIGENE Fused Heterocyclic Compounds As Protein Kinase Inhibitors
Mar, 2042

(19 years from now)

EP2989106A4 BEIGENE Fused Heterocyclic Compounds As Protein Kinase Inhibitors
Mar, 2042

(19 years from now)

Drugs and Companies using ZANUBRUTINIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
80MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.